Literature DB >> 10353490

The cannabinoid receptor agonist WIN 55,212-2 mesylate blocks the development of hyperalgesia produced by capsaicin in rats.

J Li1, R S Daughters, C Bullis, R Bengiamin, M W Stucky, J Brennan, D A Simone.   

Abstract

Although it is well known that cannabinoids produce antinociception in acute pain models, there is less information on the ability of cannabinoids to alleviate hyperalgesia. In the present study, we determined whether cannabinoids attenuated the development of hyperalgesia produced by intraplantar injection of capsaicin in rats. In normal, untreated animals, intraplantar injection of 10 microg capsaicin produces nocifensive behavior (elevation of the injected paw) suggestive of pain, an increase in the frequency of withdrawal from punctate mechanical stimuli applied to the paw (mechanical hyperalgesia) and a decrease in the latency of withdrawal from noxious heat (heat hyperalgesia). Separate groups of animals were pretreated intravenously with vehicle, the cannabinoid receptor agonist WIN 55,212-2 at doses of 1, 10, 100 or 200 microg/kg, or the enantiomer WIN 55,212-3 (100 microg/kg) 5 min before intraplantar injection of capsaicin into one paw. The duration of nocifensive behavior was measured during the first 5 min after capsaicin injection. Withdrawal responses to mechanical and heat stimuli applied to the plantar surface of both hindpaws were measured before and at 5 and 30 min after capsaicin. Pretreatment with WIN 55,212-2 produced a dose-dependent decrease in nocifensive behavior and in hyperalgesia to mechanical and heat stimuli produced by capsaicin, as compared with vehicle pretreatment. Doses of 100 and 200 microg/kg WIN 55,212-2 completely blocked the development of hyperalgesia to mechanical and heat stimuli without altering withdrawal responses on the contralateral control paw. Furthermore, these doses of WIN 55,212-2 had no effect on basal withdrawal responses to heat in animals that did not receive capsaicin. The inactive enantiomer WIN 55,212-3 did not alter the development of capsaicin-evoked pain or hyperalgesia. These data suggest that low doses of cannabinoids, which do not produce analgesia or impair motor function, attenuate chemogenic pain and possess antihyperalgesic properties.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10353490     DOI: 10.1016/s0304-3959(98)00263-2

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  18 in total

Review 1.  Endocannabinoids and exercise.

Authors:  A Dietrich; W F McDaniel
Journal:  Br J Sports Med       Date:  2004-10       Impact factor: 13.800

2.  Acute and chronic administration of the cannabinoid receptor agonist CP 55,940 attenuates tumor-evoked hyperalgesia.

Authors:  Darryl T Hamamoto; Subhalakshmi Giridharagopalan; Donald A Simone
Journal:  Eur J Pharmacol       Date:  2006-12-09       Impact factor: 4.432

Review 3.  Strategies for the treatment of cancer pain in the new millennium.

Authors:  C Ripamonti; E D Dickerson
Journal:  Drugs       Date:  2001       Impact factor: 9.546

4.  Metabotropic glutamate and cannabinoid receptor crosstalk in periaqueductal grey pain processing.

Authors:  E Palazzos; V de Novellis; I Marabese; F Rossi; S Maione
Journal:  Curr Neuropharmacol       Date:  2006-07       Impact factor: 7.363

Review 5.  Terpenes and lipids of the endocannabinoid and transient-receptor-potential-channel biosignaling systems.

Authors:  David R Janero; Alexandros Makriyannis
Journal:  ACS Chem Neurosci       Date:  2014-06-05       Impact factor: 4.418

6.  Attenuation of persistent pain-related behavior by fatty acid amide hydrolase (FAAH) inhibitors in a rat model of HIV sensory neuropathy.

Authors:  Farinaz Nasirinezhad; Stanislava Jergova; James P Pearson; Jacqueline Sagen
Journal:  Neuropharmacology       Date:  2014-12-05       Impact factor: 5.250

Review 7.  Modulation of pain transmission by G-protein-coupled receptors.

Authors:  Hui-Lin Pan; Zi-Zhen Wu; Hong-Yi Zhou; Shao-Rui Chen; Hong-Mei Zhang; De-Pei Li
Journal:  Pharmacol Ther       Date:  2007-09-22       Impact factor: 12.310

8.  Migraine: an overview.

Authors:  Salvatore Salomone; Filippo Caraci; Anna Capasso
Journal:  Open Neurol J       Date:  2009-10-01

9.  The non-selective cannabinoid receptor agonist WIN 55,212-2 attenuates responses of C-fiber nociceptors in a murine model of cancer pain.

Authors:  M L Uhelski; D M Cain; C Harding-Rose; D A Simone
Journal:  Neuroscience       Date:  2013-05-11       Impact factor: 3.590

10.  Peripheral and central sites of action for the non-selective cannabinoid agonist WIN 55,212-2 in a rat model of post-operative pain.

Authors:  C Z Zhu; J P Mikusa; Y Fan; P R Hollingsworth; M Pai; P Chandran; A V Daza; B B Yao; M J Dart; M D Meyer; M W Decker; G C Hsieh; P Honore
Journal:  Br J Pharmacol       Date:  2009-04-03       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.